Cell and organ drug targeting

Ghosh, Dipanjana; Upmanyu, Neeraj; Shukla, Tripti; Shrivastava, Tarani Prakash

doi:10.1016/b978-0-12-816505-8.00015-1

Cited by 5 publications

(3 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pegylation also reduces the immunological response and increases the solubility of the conjugated molecule [ 126 ]. PEG coating makes the nanocarrier system hydrophilic, allowing water molecules to form hydrogen bonds with oxygen molecules on the PEG, which creates a hydrated film around the nanocarrier, thereby facilitating a mitigation of the immune response to the nanocarrier [ 127 , 128 ].…”

Section: Recent Advancements In Cancer Gene Therapy Studies Using mentioning

confidence: 99%

Recent Advances in Preclinical Research Using PAMAM Dendrimers for Cancer Gene Therapy

Tarach

Janaszewska

2021

IJMS

View full text Add to dashboard Cite

Carriers of genetic material are divided into vectors of viral and non-viral origin. Viral carriers are already successfully used in experimental gene therapies, but despite advantages such as their high transfection efficiency and the wide knowledge of their practical potential, the remaining disadvantages, namely, their low capacity and complex manufacturing process, based on biological systems, are major limitations prior to their broad implementation in the clinical setting. The application of non-viral carriers in gene therapy is one of the available approaches. Poly(amidoamine) (PAMAM) dendrimers are repetitively branched, three-dimensional molecules, made of amide and amine subunits, possessing unique physiochemical properties. Surface and internal modifications improve their physicochemical properties, enabling the increase in cellular specificity and transfection efficiency and a reduction in cytotoxicity toward healthy cells. During the last 10 years of research on PAMAM dendrimers, three modification strategies have commonly been used: (1) surface modification with functional groups; (2) hybrid vector formation; (3) creation of supramolecular self-assemblies. This review describes and summarizes recent studies exploring the development of PAMAM dendrimers in anticancer gene therapies, evaluating the advantages and disadvantages of the modification approaches and the nanomedicine regulatory issues preventing their translation into the clinical setting, and highlighting important areas for further development and possible steps that seem promising in terms of development of PAMAM as a carrier of genetic material.

show abstract

Section: Recent Advancements In Cancer Gene Therapy Studies Using mentioning

confidence: 99%

Recent Advances in Preclinical Research Using PAMAM Dendrimers for Cancer Gene Therapy

Tarach

Janaszewska

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…One of the most efficient drug and gene delivery nanosystems is polyamidoamine (PAMAM) dendrimers with great physicochemical properties like symmetrical structure, biocompatibility effects, hydrophilic and non‐immunogenic which make them suitable for delivery of genetic materials 5 . Surface of PAMAM can be functionalized with different agents such as PEG, 6 antibodies, 7 peptides, 8 folic acid 9 and hydrophobic particles, 10 (TAT) 11 and different forms of polymers in order to mitigate unpleasant effects such as negative charge which affect internalization to target cells 12 …”

Section: Introductionmentioning

confidence: 99%

Development of targeted gene delivery system based on liposome and PAMAM dendrimer functionalized with hyaluronic acid and TAT peptide: In vitro and in vivo studies

Ebrahimian

Hashemi

Farzadnia

et al. 2022

Biotechnology Progress

View full text Add to dashboard Cite

The development of gene delivery systems is essential to improve their transfection efficiency and cytotoxicity. Combination of lipid and polymeric nanoparticles with the characteristics of both systems have been considered as a next‐generation gene delivery platform. In the current study, we designed a novel and efficient targeted gene delivery system based on liposome and PAMAM dendrimer in cancer cells. Two polymeric formulations containing polyamidoamine‐TAT (PAMAM‐TAT) and PAMAM‐TAT‐Hyaluronic acid (HA) and two lipopolymeric carriers including PAMAM‐TAT‐Liposome and PAMAM‐TAT‐HA‐Liposome were complexed with the enhanced green fluorescent protein (EGFP) plasmid and then evaluated in terms of physicochemical characteristics. The cytotoxicity and transfection efficiency of these synthetized carriers were accomplished against murine colon carcinoma cell line (C26). The biodistribution of polyplexes and lipoployplexes was also evaluated in the C26 tumor bearing mice. The results showed no significant toxicity for all designed nanoparticles (NPs) in C/P4. The highest gene expression was observed using lipopolyplex PAMAM‐TAT‐HA‐Liposome in C/P4 (ratio polymer/DNA; wt/wt). Biodistribution study demonstrated more aggregation of targeted lipopolyplex in tumor cells than other nanoparticles (NPs). It could be concluded that the developed targeted lipopolymeric complex could serve as promising nanotherapeutic system for gene therapy.

show abstract

“…Nanocarrier systems offer several advantages such as small sizes compatible with intravenous injection, large surface area per unit volume which enables the alteration of the basic properties and bioavailability of the encapsulated drugs, improved pharmacokinetics, and biodistribution, decreased toxicities, improved solubility and stability, increased circulation time, site-specific delivery of therapeutic agents through surface functionalization, improved patient compliance by reducing the dose and administration frequency and reduced systemic side effects [2], [3]. For this purpose, various nanocarriers with unique compositions, morphologies, and surface properties have been developed including, dendrimers, micelles, carbon nanotubes (CNTs), quantum dots (QDs), gold nanoparticles (Au NPs), metal organic frameworks (MOFs), solid lipid nanoparticles (SLNs) and liposomes [4].…”

Section: Introductionmentioning

confidence: 99%

Modeling of Anti-Cancer Drug Release Kinetics From Liposomes and Micelles: A Review

Sawaftah

Paul

Awad

et al. 2021

IEEE Trans.on Nanobioscience

View full text Add to dashboard Cite

Nanocarriers such as micelles and liposomes were developed to enhance the delivery of therapeutic drugs to tumors. Internal or external stimuli can be applied to achieve spatiotemporal controlled release from these carriers. This will result in enhancing the therapeutic efficacy of anti-neoplastic drugs while reducing their toxicity. Mathematical modeling is used to simulate drug release from nanocarriers; this will facilitate and optimize the development and design of desirable nanocarriers in a systematic manner, rather than the existing trial-and-error approach. This review summarizes nine mathematical models often used to simulate drug release from drug delivery systems and reviews studies that employed these models to simulate drug release from conventional micelles and liposomes, as well as temperature-, pH-, and ultrasound-triggered micelles and liposomes.

show abstract

Cell and organ drug targeting

Cited by 5 publications

References 69 publications

Recent Advances in Preclinical Research Using PAMAM Dendrimers for Cancer Gene Therapy

Recent Advances in Preclinical Research Using PAMAM Dendrimers for Cancer Gene Therapy

Development of targeted gene delivery system based on liposome and PAMAM dendrimer functionalized with hyaluronic acid and TAT peptide: In vitro and in vivo studies

Modeling of Anti-Cancer Drug Release Kinetics From Liposomes and Micelles: A Review

Contact Info

Product

Resources

About